Bortezomib for the Treatment of Mantle Cell Lymphoma

Purpose: To describe the Food and Drug Administration review and marketing approval considerations for bortezomib (Velcade) for the treatment of patients with mantle cell lymphoma. Experimental Design: Food and Drug Administration reviewed a multicenter study of bortezomib in 155 patients with progr...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2007-09, Vol.13 (18), p.5291-5294
Hauptverfasser:	KANE, Robert C, DAGHER, Ramzi, FARRELL, Ann, KO, Chia-Wen, SRIDHARA, Rajeshwari, JUSTICE, Robert, PAZDUR, Richard
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antineoplastic agents Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Biological and medical sciences Boronic Acids - adverse effects Boronic Acids - therapeutic use Bortezomib Drug Approval Female Hematologic and hematopoietic diseases Humans Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Lymphoma, Mantle-Cell - drug therapy Male mantle cell lymphoma Medical sciences Pharmacology. Drug treatments Prospective Studies Pyrazines - adverse effects Pyrazines - therapeutic use regular approval United States United States Food and Drug Administration Velcade
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!